Abstract: A method for determining a consistency coefficient of a power-law cement grout includes: determining a water-cement ratio of the power-law cement grout; according to engineering practice requirements, determining a time required to determine the consistency coefficient of the power-law cement grout; and obtaining the consistency coefficient of the power-law cement grout. The method is accurate and reliable, requires less calculation, etc.; and has very high practical value and popularization value in environmental protection and ecological restoration.

Abstract: The present invention provides pharmaceutical formulations comprising 1,3,5-triazine derivatives. The compounds and formulations of the present invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivatives of the present invention bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.

Abstract: Disclosed are pharmaceutical compositions comprising aryl and heteroaryl hydrazone, hydrazine and thiosemicarbazone derivatives of formulae I and II, and methods for using the compositions as antifungal agents. The invention also relates to novel aryl and heteroaryl hydrazone, hydrazine and thiosemicarbazone derivatives of formulae I and II, their preparation, to pharmaceutical compositions containing them, and to methods of using them to alleviate fungal infections.

Abstract: Disclosed are pharmaceutical compositions and formulations comprising benzoquinoline derivatives having the formula (I) to (V), wherein formula (I) is: X is selected from the group consisting of O, S, CH2, CH2-CH2, C═O or NRB; Y is C or N; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, linear or branched chain lower alky, alkenyl, alkynyl, alkoxy or acyl; X-RA and R3, or R3 and R4, are optionally linked together to form a C3-C4 alkylene bridge, where X is CH2 or C═O; provided that: when X is NRB, then (a) RB is hydrogen, and RA is a linear or branched chain lower alkyl, aryl, heteroaryl, cycloalkyl or cycloalkenyl optionally interrupted by at least one heteroatom, said alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or cycloalkenyl being optionally substituted singly or plurally by at least one of a linear or branched chain lower alkyl, alkenyl, alkynyl, acyl, alkoxy, or cycloalkyl optionally interrupted by at least one heter

Abstract: Disclosed are pharmaceutical compositions and formulations comprising the compound: wherein: (a) R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, or optionally substituted alkyl, aryl, vinyl, alkyl(aryl), vinyl(aryl), amine, amide; or at least one of R1 and R2, together, and R3 and R4, together, form an optionally substituted ring system, wherein the ring system is optionally interrupted by at least one heteroatom; (b) X is hydrogen, NO2, CN, halogen, OH, SO2, alkyl, alkoxy, or vinyl; and (c) wherein when R1, R2, R3, and R4 are alkyl, aryl, vinyl, alkyl(aryl), vinyl(aryl), amine or amide, R1, R2, R3, and R4 are optionally interrupted with at least one heteroatom, or a salt thereof; and a pharmaceutically acceptable carrier or diluent. Also disclosed are methods of inhibiting microbial replication and treating microbial infections, comprising administration of a pharmaceutical composition or formulation of the invention.

Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.